beta-Escin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
beta-Escin is an anti-inflammatory and vasoconstrictive agent indicated to treat minor muscle and joint trauma.
- Generic Name
- beta-Escin
- DrugBank Accession Number
- DB15774
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 1131.269
Monoisotopic: 1130.550903649 - Chemical Formula
- C55H86O24
- Synonyms
- Aescin B
- beta-Aescin
- beta-Escin
- External IDs
- EINECS 247-619-4
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination for symptomatic treatment of Back pain lower back Combination Product in combination with: Salicylic acid (DB00936) •••••••••••• •••• ••••• Used in combination for symptomatic treatment of Back pain, unspecified Combination Product in combination with: Salicylic acid (DB00936) •••••••••••• •••• ••••• Treatment of Capillary fragility •••••••••••• •••••••••• ••••••• ••• ••••••••• •••••• Used in combination for symptomatic treatment of Cervical syndrome Combination Product in combination with: Salicylic acid (DB00936) •••••••••••• •••• ••••• Used in combination for symptomatic treatment of Sciatica Combination Product in combination with: Salicylic acid (DB00936) •••••••••••• •••• ••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Flogencyl
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Reparil 20mgTablets Tablet 20 mg Oral MYLAN HEALTHCARE SDN. BHD. 2020-09-08 Not applicable Malaysia - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image JELGO %1 + % 5 JEL, 50 GRAM beta-Escin (1 %) + Diethylamine salicylate (5 %) Gel Topical TRIPHARMA İLAÇ SAN. VE TİC. A.Ş. 2017-04-07 Not applicable Turkey PREPA-S SPREY, 100 ML beta-Escin (0.025 g/ml) + Diethylamine salicylate (0.125 g/ml) Spray Topical RECORDATİ İLAÇ SAN. VE TİC. A.Ş. 2010-07-16 Not applicable Turkey PREPAGEL %1+%5 JEL, 40 G beta-Escin (1 %) + Diethylamine salicylate (5 %) Gel Topical RECORDATİ İLAÇ SAN. VE TİC. A.Ş. 1997-07-25 Not applicable Turkey RECTOREPARIL beta-Escin (0.5 %) + Tetracaine hydrochloride (4.5 %) Ointment Topical Viatris Limited 2014-07-08 2023-08-12 Italy RECTOREPARIL beta-Escin (4.5 %) + Tetracaine hydrochloride (0.5 %) Cream Rectal Viatris Limited 2014-07-08 2023-08-12 Italy
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- QYK0D6H79O
- CAS number
- 26339-90-2
- InChI Key
- AXNVHPCVMSNXNP-OXPBSUTMSA-N
- InChI
- InChI=1S/C55H86O24/c1-10-23(2)46(71)79-43-44(72-24(3)60)55(22-59)26(17-50(43,4)5)25-11-12-30-51(6)15-14-32(52(7,21-58)29(51)13-16-53(30,8)54(25,9)18-31(55)61)75-49-41(77-48-38(67)36(65)34(63)28(20-57)74-48)39(68)40(42(78-49)45(69)70)76-47-37(66)35(64)33(62)27(19-56)73-47/h10-11,26-44,47-49,56-59,61-68H,12-22H2,1-9H3,(H,69,70)/b23-10-/t26-,27+,28+,29+,30+,31+,32-,33+,34+,35-,36-,37+,38+,39-,40-,41+,42-,43-,44-,47-,48-,49+,51-,52+,53+,54+,55-/m0/s1
- IUPAC Name
- (2S,3S,4S,5R,6R)-6-{[(3S,4S,4aR,6aR,6bS,8R,8aR,9R,10R,12aS,14aR,14bR)-9-(acetyloxy)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-{[(2Z)-2-methylbut-2-enoyl]oxy}-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-4-hydroxy-3,5-bis({[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxane-2-carboxylic acid
- SMILES
- [H][C@@]1(O[C@H]2[C@H](O)[C@@H](O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@]([H])(O[C@H]3CC[C@@]4(C)[C@@]([H])(CC[C@]5(C)[C@]4([H])CC=C4[C@]6([H])CC(C)(C)[C@@H](OC(=O)C(\C)=C/C)[C@H](OC(C)=O)[C@]6(CO)[C@H](O)C[C@@]54C)[C@@]3(C)CO)O[C@@H]2C(O)=O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
References
- General References
- AIFA Product Information: EDEVEXIN (beta-Escin) injection and tablet [Link]
- External Links
- KEGG Compound
- C08921
- ChemSpider
- 4977652
- BindingDB
- 50466108
- 1476
- ChEBI
- 2500
- ChEMBL
- CHEMBL505939
- Wikipedia
- Deserpidine
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Gel Topical 1 % Gel Topical 2 % Powder, for solution Intravenous 5 MG/5ML Tablet, coated Oral 40 MG Spray Topical Cream Rectal Tablet Oral 20 mg Gel Topical Ointment Topical Suppository Rectal - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.773 mg/mL ALOGPS logP 1.17 ALOGPS logP -0.88 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 3.35 Chemaxon pKa (Strongest Basic) -3.6 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 22 Chemaxon Hydrogen Donor Count 13 Chemaxon Polar Surface Area 388.04 Å2 Chemaxon Rotatable Bond Count 16 Chemaxon Refractivity 269.78 m3·mol-1 Chemaxon Polarizability 118.85 Å3 Chemaxon Number of Rings 8 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at August 21, 2020 14:21 / Updated at May 14, 2021 01:07